Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity

Hong, A; Piva, M; Liu, SX; Hugo, W; Lomeli, SH; Zoete, V; Randolph, CE; Yang, ZT; Wang, Y; Lee, JJ; Lo, SJ; Sun, L; Vega-Crespo, A; Garcia, AJ; Shackelford, DB; Dubinett, SM; Scumpia, PO; Byrum, SD; Tackett, AJ; Donahue, TR; Michielin, O; Holmen, SL; Ribas, A; Moriceau, G; Lo, RS

Moriceau, G; Lo, RS (corresponding author), Univ Calif Los Angeles, 10833 Le Conte Ave 52-121 CHS, Los Angeles, CA 90095 USA.

CANCER DISCOVERY, 2021; 11 (3): 714

Abstract

MAPK targeting in cancer often fails due to MAPK reactivation. MEK inhibitor (MEKi) monotherapy provides limited clinical benefits but may serve as a ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索